At the 2024 annual meeting of the American Society of Hematology (ASH), held on 7 December in San Diego, California, ...

Trying to break from the decade-old practice of using BTK inhibitors indefinitely to treat blood cancer, AstraZeneca has ...

AstraZeneca is getting ready to step on the gas in the world of bispecific T cell engagers. The company presented some of its ...

The U.S. Food and Drug Administration has approved AstraZeneca blockbuster drug Imfinzi to treat some adults with ...

AstraZeneca has picked off another label expansion for its cancer blockbuster Imfinzi (durvalumab) as the FDA has ...

The US Food and Drug Administration (FDA) has granted priority review to AstraZeneca's supplemental biologics licence ...

▎药明康德内容团队编辑阿斯利康（AstraZeneca）今日宣布其重磅PD-L1抑制剂Imfinzi（durvalumab）已获得美国FDA的批准，用于治疗接受铂类同步放化疗（cCRT）后病情未进展的局限期小细胞肺癌（LS-SCLC）成人患者。小细胞 ...

"The breakthrough therapy designation granted by the FDA underscores the significant unmet need for new treatments for patients with previously treated EGFR-mutated non-small cell lung cancer who have ...

AstraZeneca and Daiichi Sankyo have shared the data they believe can secure approval for datopotamab deruxtecan (Dato-DXd) at ...

British drug maker AstraZeneca Plc (AZN.L, AZN) announced Thursday that the U.S. Food and Drug Administration has approved Imfinzi ...

AstraZeneca's Imfinzi (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small ...

Imfinzi (durvalumab) for adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed ...